Stay updated on Sacituzumab + Pembrolizumab in Metastatic TNBC Clinical Trial
Sign up to get notified when there's something new on the Sacituzumab + Pembrolizumab in Metastatic TNBC Clinical Trial page.

Latest updates to the Sacituzumab + Pembrolizumab in Metastatic TNBC Clinical Trial page
- Check5 days agoChange DetectedAdded the principal investigator, Lauren Carcas, MD, and contact email; expanded recruitment sites to Kendall and Plantation, FL (Miami Cancer Institute at Baptist Health), bringing total locations to 14, and updated the Last Update Posted (Estimated) to 2025-12-03.SummaryDifference1%

- Check13 days agoNo Change Detected
- Check20 days agoChange DetectedPublications are now described as automatically filled from PubMed and the page records Revision: v3.3.2, replacing the previous wording tied to PubMed-derived entries and Revision: v3.2.0.SummaryDifference0.1%

- Check27 days agoChange DetectedThe page no longer displays the general government funding status notice, a site-wide banner not specific to the study details. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check49 days agoChange DetectedNo significant changes detected; minor wording and formatting adjustments across the study page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check70 days agoChange Detected- Added a prominent operations/uptime notice and current status guidance, including a link to cc.nih.gov and opm.gov. - Updated the version to v3.2.0. - Removed the previous version tag v3.1.0.SummaryDifference2%

- Check77 days agoChange Detected- Updated page revision to v3.1.0 and added multiple contact emails. - Removed reference to the older revision v3.0.2. No other substantive content changes detected.SummaryDifference0.0%

Stay in the know with updates to Sacituzumab + Pembrolizumab in Metastatic TNBC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Sacituzumab + Pembrolizumab in Metastatic TNBC Clinical Trial page.